Statement of Principles
centering
GUILLAIN-BARRE SYNDROME
(Balance of Probabilities)
(No. 24 of 2018)

The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.

Dated 2 March 2018

The Common Seal of the
Repatriation Medical Authority
was affixed to this instrument
at the direction of:

[Signature]

Professor Nicholas Saunders AO
Chairperson
1 Name

This is the Statement of Principles concerning Guillain-Barre syndrome (Balance of Probabilities) (No. 24 of 2018).

2 Commencement

This instrument commences on 2 April 2018.

3 Authority

This instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986.

4 Revocation

The Statement of Principles concerning Guillain-Barre syndrome No. 60 of 2013 made under subsection 196B(3) of the VEA is revoked.

5 Application

This instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.

6 Definitions

The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.

7 Kind of injury, disease or death to which this Statement of Principles relates

(1) This Statement of Principles is about Guillain-Barre syndrome and death from Guillain-Barre syndrome.

Meaning of Guillain-Barre syndrome

(2) For the purposes of this Statement of Principles, Guillain-Barre syndrome:

(a) means an acute or subacute immune-mediated disorder of the peripheral nervous system producing symptoms and signs of impaired motor, sensory or autonomic functioning; and

(b) includes:

(i) acute inflammatory demyelinating polyneuropathy;
(ii) acute motor axonal neuropathy;
(iii) acute motor sensory axonal neuropathy;
(iv) Miller Fisher syndrome; and
(v) other variant forms of Guillain-Barre syndrome; and

(c) excludes chronic inflammatory demyelinating polyneuropathy.
Note 1: The most common variant of Guillain-Barre syndrome is acute inflammatory demyelinating polyneuropathy, which is characterised by rapidly progressive symmetrical limb weakness, loss of tendon reflexes, mild sensory signs and variable autonomic dysfunction.

Note 2: The diagnosis of Guillain-Barre syndrome is normally confirmed by electrodiagnostic testing or elevated protein concentration in cerebrospinal fluid without an elevated white cell count (cytoalbuminologic dissociation).

(3) While Guillain-Barre syndrome attracts ICD-10-AM code G61.0, in applying this Statement of Principles the meaning of Guillain-Barre syndrome is that given in subsection (2).


Death from Guillain-Barre syndrome

(5) For the purposes of this Statement of Principles, Guillain-Barre syndrome, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's Guillain-Barre syndrome.

Note: terminal event is defined in the Schedule 1 – Dictionary.

8 Basis for determining the factors

On the sound medical-scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that Guillain-Barre syndrome and death from Guillain-Barre syndrome can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.

Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.

9 Factors that must exist

At least one of the following factors must exist before it can be said that, on the balance of probabilities, Guillain-Barre syndrome or death from Guillain-Barre syndrome is connected with the circumstances of a person's relevant service:

(1) having an infection with an organism from the specified list of infections, where that infection has been acquired within the two months before the clinical onset of Guillain-Barre syndrome;

Note: specified list of infections is defined in the Schedule 1 - Dictionary.

(2) being infected with human immunodeficiency virus at the time of the clinical onset of Guillain-Barre syndrome;
(3) having a clinically apparent herpes zoster infection in the two months before the clinical onset of Guillain-Barre syndrome;

(4) having a symptomatic gastrointestinal or respiratory tract infection in the two months before the clinical onset of Guillain-Barre syndrome;

(5) receiving an influenza vaccine or a nerve tissue derived rabies vaccine within the two months before the clinical onset of Guillain-Barre syndrome;

(6) having a malignant neoplasm, other than non-melanotic malignant neoplasm of the skin, at the time of the clinical onset of Guillain-Barre syndrome;

(7) having a solid organ or stem cell transplant before the clinical onset of Guillain-Barre syndrome;

(8) being treated with a tumour necrosis factor-α inhibitor in the two months before the clinical onset of Guillain-Barre syndrome;

(9) inability to obtain appropriate clinical management for Guillain-Barre syndrome.

10 Relationship to service

(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.

(2) The factor set out in subsection 9(9) applies only to material contribution to, or aggravation of, Guillain-Barre syndrome where the person's Guillain-Barre syndrome was suffered or contracted before or during (but did not arise out of) the person's relevant service.

11 Factors referring to an injury or disease covered by another Statement of Principles

In this Statement of Principles:

(1) if a factor referred to in section 9 applies in relation to a person; and

(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;

then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.
Note: See Section 6

1 Definitions

In this instrument:

**Guillain-Barre syndrome**—see subsection 7(2).

**MRCA** means the *Military Rehabilitation and Compensation Act 2004*.

**relevant service** means:

(a) eligible war service (other than operational service) under the VEA;
(b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or
(c) peacetime service under the MRCA.

Note: **MRCA** and **VEA** are also defined in the Schedule 1 - Dictionary.

**specified list of infections** means:

(a) *Campylobacter jejuni*;
(b) Chikungunya virus;
(c) cytomegalovirus;
(d) dengue virus;
(e) Epstein-Barr virus;
(f) hepatitis A virus;
(g) hepatitis E virus;
(h) influenza virus;
(i) Japanese encephalitis virus;
(j) *Mycoplasma pneumoniae*;
(k) *Orientia tsutsugamushi* (scrub typhus);
(l) West Nile virus; or
(m) Zika virus.

**terminal event** means the proximate or ultimate cause of death and includes the following:

(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e) cessation of brain function.

**VEA** means the *Veterans’ Entitlements Act 1986*. 

---

**Statement of Principles concerning**

**Guillain-Barre Syndrome (Balance of Probabilities) (No. 24 of 2018)**

**Veterans’ Entitlements Act 1986**